4 - NEUROCRINE BIOSCIENCES INC (0000914475) (Issuer)

4 - NEUROCRINE BIOSCIENCES INC (0000914475) (Issuer)

4 - NEUROCRINE BIOSCIENCES INC (0000914475) (Issuer)

4 - NEUROCRINE BIOSCIENCES INC (0000914475) (Issuer)

4 - NEUROCRINE BIOSCIENCES INC (0000914475) (Issuer)

4 - NEUROCRINE BIOSCIENCES INC (0000914475) (Issuer)

4 - NEUROCRINE BIOSCIENCES INC (0000914475) (Issuer)

4 - NEUROCRINE BIOSCIENCES INC (0000914475) (Issuer)

4 - NEUROCRINE BIOSCIENCES INC (0000914475) (Issuer)

4 - NEUROCRINE BIOSCIENCES INC (0000914475) (Issuer)

Data Support Positive Impact of INGREZZA in People With Huntington's Disease ChoreaFindings Presented at the 2024 Annual Meeting of the Huntington Study GroupSAN DIEGO, Nov. 7, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) today presented subgroup analyses and data from the KINECT®-HD study showing the impact of INGREZZA® (valbenazine) capsules on emotional health and psychiatric stability in patients with chorea associated with Huntington's disease. The subgroup analysis showed consistent efficacy in reducing chorea compared to placebo across all identified subgroups, categorized by demographics and baseline assessment scores. A separate data analysis showed improvements i

2024 UBS Global Healthcare Conference on November 12 Stifel 2024 Healthcare Conference on November 18 Jefferies London Healthcare Conference on November 19 SAN DIEGO, Nov. 5, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) will participate at three upcoming investor conferences in November. Chief Executive Officer Kyle Gano, Chief Financial Officer Matt Abernethy, and Vice-President of Investor Relations Todd Tushla will present at the 2024 UBS Global Healthcare Conference at 1:15 p.m. Pacific Time (4:15 p.m. Eastern Time) on Tuesday November 12, 2024 in Rancho

Findings Presented at the 2024 Psych Congress Include Data From More Than 300 PatientsSAN DIEGO, Nov. 4, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) presented data from more than 300 patients diagnosed with tardive dyskinesia and treated with INGREZZA® (valbenazine) capsules. These data showed significant improvements in functional, social, emotional and health-related quality of life measures in Phase 3 and 4 studies and improvements in functional, social, independence, emotional and physical aspects of patients' lives and antipsychotic adherence in real-world practice. This research was shared at the 2024 Psych Congress in Boston.

SAN DIEGO, Nov. 4, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) presented data from the long-term KINECT®-4 study demonstrating tardive dyskinesia remission in nearly 60% of participants at Week 48 with once-daily INGREZZA® (valbenazine) capsules treatment. This research, "Remission of Tardive Dyskinesia in Patients Receiving Long-Term Valbenazine Treatment" (Poster #98), was shared at the 2024 Psych Congress in Boston. "Tardive dyskinesia is persistent and irreversible, and effective treatment over time can have a positive impact for patients who are alread

INGREZZA® (valbenazine) Third Quarter Net Product Sales of $613 Million Representing 26% Year-Over-Year Growth INGREZZA® (valbenazine) 2024 Net Product Sales Guidance Raised to $2.30 - $2.32 Billion Board Authorizes $300 Million Share Repurchase Plan SAN DIEGO, Oct. 30, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) today announced its financial results for the third quarter ended September 30, 2024 and provided an update on its 2024 financial guidance. "With continued INGREZZA growth across the tardive dyskinesia and Huntington's disease chorea indications,

Conference Call and Webcast Scheduled for Wednesday, October 30 SAN DIEGO, Oct. 9, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) announced today that it has scheduled its third quarter 2024 financial results conference call and webcast for 5:00 a.m. Pacific Time (8:00 a.m. Eastern Time) on October 30, 2024. The schedule for the press release and conference call / webcast is as follows: • Q3 2024 Press Release:          October 30, 2024 at 4:00 a.m. PT / 7:00 a.m. ET • Q3 2024 Conference Call:        October 30, 2024 at 5:00 a.m. PT / 8:00 a.m. ET • Domestic D

KINECT®-HD2 Is the First Prospective Clinical Trial to Include Patients Taking Antipsychotic Medication in a Study Evaluating a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor for the Treatment of Huntington's Disease Chorea Findings Presented at the 2024 MDS International Congress of Parkinson's Disease and Movement Disorders®SAN DIEGO, Sept. 30, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) today announced interim results from the ongoing open-label KINECT®-HD2 study of INGREZZA® (valbenazine) capsules for the long-term treatment of adults with chorea associated with Huntington's disease. Robust and sustained improvements in chorea associated with Huntington's disease

SAN DIEGO, Sept. 19, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) will participate at the TD Cowen 4th Annual Novel Mechanisms in Neuropsychiatry Virtual Summit at 11:00 a.m. Eastern Time on Thursday, September 26, 2024. Chief Business Development and Strategy Officer and CEO-elect Kyle Gano and Vice-President of Investor Relations Todd Tushla will present at the conference. The live presentation will be webcast and may be accessed on Neurocrine Biosciences' website under Investors at www.neurocrine.com. A replay of the webcast will be available on the websi

Second Phase 2 Study for Luvadaxistat Fails to Meet Primary Endpoint as Potential Treatment for Cognitive Impairment Associated with SchizophreniaResults Confounded by Variability in Cognition Measures Across Population Studied and Potential Imbalance in Baseline Characteristics of Enrolled SubjectsNeurocrine Biosciences to Focus Resources on Phase 3 Clinical Development of NBI-1117568 for Schizophrenia and NBI-1065845 for Major Depressive DisorderSAN DIEGO, Sept. 12, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) today announced that its ERUDITE™ Phase 2 clinical study of investigational compound luvadaxistat (NBI-1065844) failed to meet its primary endpoint as a potential

SAN DIEGO, Sept. 10, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) will participate at the 2024 Cantor Global Healthcare Conference in New York at 3:05 p.m. Eastern Time on Tuesday, September 17, 2024. Chief Business Development and Strategy Officer and CEO-elect Kyle Gano, Chief Financial Officer Matt Abernethy, and Vice-President of Investor Relations Todd Tushla will present at the conference. The live presentation will be webcast and may be accessed on Neurocrine Biosciences' website under Investors at www.neurocrine.com. A replay of the webcast will be a

Cantor Fitzgerald analyst Charles Duncan reiterates Neurocrine Biosciences (NASDAQ:NBIX) with a Overweight and maintains $155 price target.

Needham analyst Ami Fadia reiterates Neurocrine Biosciences (NASDAQ:NBIX) with a Hold.

Morgan Stanley analyst Jeffrey Hung maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Overweight and raises the price target from $160 to $170.

Analysts' ratings for Neurocrine Biosciences (NASDAQ:NBIX) over the last quarter vary from bullish to bearish, as provided by 16 analysts. The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 5 9 2 0 0 Last 30D 0 1 0 0 0 1M Ago 0 1 0 0 0 2M Ago 1 2 0 0 0 3M Ago 4 5 2 0 0 The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $167.94, a high estimate of $216.00, and a low estimate of $138.00. This upward trend is apparent, with the current

JP Morgan analyst Anupam Rama maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Overweight and raises the price target from $169 to $173.

 Neurocrine Biosciences, Inc. (NASDAQ:NBIX) today announced the U.S. Food and Drug Administration (FDA) has accepted its two New Drug Applications (NDA) with Priority Review designations for crinecerfont in the treatment of children, adolescents and adults with classic congenital adrenal hyperplasia (CAH). If approved, crinecerfont would be the first new treatment option for CAH in 70 years and a first-in-class therapy, with a novel approach for the treatment of this rare and serious endocrine disorder. The submitted crinecerfont NDAs included: the primary presentation of efficacy and safety of crinecerfont for the treatment of classic CAH as (1) a capsule formulation (NDA# 218808); and (

Morgan Stanley analyst Jeffrey Hung maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Overweight and maintains $160 price target.

INGREZZA® (valbenazine) Third Quarter Net Product Sales of $613 Million Representing 26% Year-Over-Year Growth INGREZZA® (valbenazine) 2024 Net Product Sales Guidance Raised to $2.30 - $2.32 Billion Board Authorizes $300 Million Share Repurchase Plan SAN DIEGO, Oct. 30, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) today announced its financial results for the third quarter ended September 30, 2024 and provided an update on its 2024 financial guidance. "With continued INGREZZA growth across the tardive dyskinesia and Huntington's disease chorea indications,

Conference Call and Webcast Scheduled for Wednesday, October 30 SAN DIEGO, Oct. 9, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) announced today that it has scheduled its third quarter 2024 financial results conference call and webcast for 5:00 a.m. Pacific Time (8:00 a.m. Eastern Time) on October 30, 2024. The schedule for the press release and conference call / webcast is as follows: • Q3 2024 Press Release:          October 30, 2024 at 4:00 a.m. PT / 7:00 a.m. ET • Q3 2024 Conference Call:        October 30, 2024 at 5:00 a.m. PT / 8:00 a.m. ET • Domestic D

NBI-1117568 is an oral, muscarinic M4 selective receptor agonist discovered by Nxera advancing through clinical development under a multi-program collaboration with Neurocrine BiosciencesThe once-daily 20 mg dose efficacy, safety and tolerability Phase 2 results support advancement to Phase 3 in schizophrenia in early 2025The once-daily 20 mg dose met the primary endpoint, demonstrating a statistically significant 7.5-point improvement (p=0.011, 0.61 effect size) in the PANSS total score compared to placebo at week 6 with an 18.2-point PANSS total score improvement from baselineThe once-daily 20 mg dose met additional endpoints, demonstrating statistically significant improvements in Clinica

The Once-Daily 20 mg Dose Met the Primary Endpoint, Demonstrating a Statistically Significant 7.5-Point Improvement (p=0.011, 0.61 Effect Size) in the PANSS Total Score Compared to Placebo at Week 6 with an 18.2-Point PANSS Total Score Improvement from BaselineThe Once-Daily 20 mg Dose Met Additional Endpoints, Demonstrating Statistically Significant Improvements in Clinical Global Impression of Severity Scale and Marder Factor Score Positive Symptom Change and Negative Symptom ChangeNBI-'568 Was Generally Safe and Well Tolerated at All Doses StudiedThe Once-Daily 20 mg Dose Efficacy, Safety and Tolerability Phase 2 Results Support Advancement to Phase 3 in Schizophrenia in Early 2025Company

INGREZZA® (valbenazine) Second Quarter Net Product Sales of $580 Million Representing 32% Year-Over-Year Growth INGREZZA® (valbenazine) 2024 Net Product Sales Guidance Raised to $2.25 - $2.3 Billion Top-Line Phase 2 Data Readouts for NBI-'568 and Luvadaxistat Remain On Track in Q3 SAN DIEGO, Aug. 1, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) today announced its financial results for the second quarter ended June 30, 2024 and provided an update on its 2024 financial guidance. "At Neurocrine, we are energized by the tremendous opportunity we see to help many

Conference Call and Webcast Scheduled for Thursday, August 1 SAN DIEGO, July 11, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) announced today that it has scheduled its second quarter 2024 financial results conference call and webcast for 5:00 a.m. Pacific Time (8:00 a.m. Eastern Time) on August 1, 2024. The schedule for the press release and conference call / webcast is as follows: • Q2 2024 Press Release:    August 1, 2024 at 4:00 a.m. PT / 7:00 a.m. ET • Q2 2024 Conference Call:          August 1, 2024 at 5:00 a.m. PT / 8:00 a.m. ET • Domestic Dial-In Numb

INGREZZA® (valbenazine) First Quarter Net Product Sales of $506 Million Representing 23% Year-Over-Year Growth INGREZZA® SPRINKLE (valbenazine) Capsules Approved by the U.S. FDA Crinecerfont New Drug Applications for the Treatment of Congenital Adrenal Hyperplasia Submitted to the U.S. FDA Positive Phase 2 Top-Line Data for NBI-1065845, a Potential First-In-Class AMPA Positive Allosteric Modulator, in Adults with Major Depressive Disorder SAN DIEGO, May 1, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) today announced its financial results for the first quarter ended March 31, 2024 and provided an update on its 2024 financial guidance.

Conference Call and Webcast Scheduled for Wednesday, May 1 SAN DIEGO, April 10, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) announced today that it has scheduled its first quarter 2024 financial results conference call and webcast for 5:00 a.m. Pacific Time (8:00 a.m. Eastern Time) on May 1, 2024. The schedule for the press release and conference call / webcast is as follows: • Q1 2024 Press Release: May 1, 2024 at 4:00 a.m. PT / 7:00 a.m. ET • Q1 2024 Conference Call: May 1, 2024 at 5:00 a.m. PT / 8:00 a.m. ET • Domestic Dial-In Number: 800-343-4136

INGREZZA® (valbenazine) Fourth Quarter and Full Year 2023 Net Product Sales of $500 Million and $1.84 Billion, Representing Year-over-Year Growth of 25% and 29% Respectively INGREZZA® (valbenazine) Full Year 2024 Net Product Sales Guidance of $2.1 - $2.2 Billion Crinecerfont FDA Regulatory Submission Anticipated in the Second Quarter for the Treatment of Congenital Adrenal Hyperplasia in Adults and Pediatrics SAN DIEGO, Feb. 7, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) today announced its financial results for the fourth quarter and full year ended December 31, 2023 and provided financial guidance for 2024.

Conference Call and Webcast Scheduled for Wednesday, February 7 SAN DIEGO, Jan. 17, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) announced today that it has scheduled its fourth quarter and year-end 2023 financial results conference call and webcast for 5:00 a.m. Pacific Time (8:00 a.m. Eastern Time) on February 7, 2024. The schedule for the press release and conference call / webcast is as follows: •  Q4 & Year-End 2023 Press Release:                February 7, 2024 at 4:00 a.m. PT / 7:00 a.m. ET • Q4 & Year-End 2023 Conference Call:          February 7, 20

Board of Directors appoints Kyle Gano, Ph.D., Chief Business Development and Strategy Officer, as CEO-elect, effective October 11, 2024 Kevin Gorman, Ph.D., to continue to serve on the Neurocrine Board of Directors SAN DIEGO, May 28, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ:NBIX), today announced that Kevin Gorman, Ph.D., will retire as Chief Executive Officer of Neurocrine on October 11, 2024. Kyle Gano, Ph.D., currently Neurocrine's Chief Business Development and Strategy Officer, will succeed him in the CEO role. Dr. Gano will also join the Company's Board of Directors at that time, and Dr. Gorman will continue to serve on the Neurocrine Board.

SAN DIEGO, July 11, 2023 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) today announced that it appointed Christine A. Poon, a business leader with extensive experience in the pharmaceutical industry, to its Board of Directors. "Christine Poon brings a wealth of industry experience to Neurocrine's Board of Directors," said William H. Rastetter, Chairman of the Board of Neurocrine Biosciences. "Her strong track record in leadership positions at some of the most established global biopharmaceutical enterprises will serve Neurocrine well." Ms. Poon has demonstrated br

SAN DIEGO, Sept. 29, 2022 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) announced today that Dr. Ingrid Delaet will join the company's executive management team as Chief Regulatory Officer effective October 1, leading the regulatory affairs, quality assurance, medical writing, and program management teams. Dr. Delaet has served as Vice President of Regulatory Affairs at Neurocrine since January 2021. "Ingrid's deep experience in regulatory affairs will be invaluable to Neurocrine as we work to advance our pipeline in our quest to relieve suffering for people with

SAN DIEGO, Nov. 30, 2021 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) announced today that Jude Onyia, Ph.D., has joined the company's executive management team as Chief Scientific Officer. Dr. Onyia, a scientist with more than 25 years of experience in the pharmaceutical industry, will lead the drug discovery and non-clinical development teams responsible for bolstering and advancing the company's pipeline of therapeutic candidates. Dr. Onyia most recently was the Chief Scientific Officer at Capsida Biotherapeutics. Prior to that, he spent 25 years at Eli Lilly

SAN DIEGO, April 16, 2021 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) today announced the appointment of Johanna Mercier to its Board of Directors. Ms. Mercier is the Chief Commercial Officer of Gilead Sciences, with responsibility for the global commercialization of Gilead's medicines. "We are pleased to add Johanna Mercier to the Board of Directors at Neurocrine Biosciences," said William H. Rastetter, Chairman of the Board of Neurocrine Biosciences. "Johanna is an accomplished commercial leader and her extensive global experience within the biopharmaceutical